GOVX Logo

GeoVax Labs, Inc. (GOVX) 

NASDAQ
Market Cap
$22.08M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
339 of 968
Rank in Industry
204 of 556

Largest Insider Buys in Sector

GOVX Stock Price History Chart

GOVX Stock Performance

About GeoVax Labs, Inc.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Insider Activity of GeoVax Labs, Inc.

Over the last 12 months, insiders at GeoVax Labs, Inc. have bought $43,421 and sold $0 worth of GeoVax Labs, Inc. stock.

On average, over the past 5 years, insiders at GeoVax Labs, Inc. have bought $46,191 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: DODD DAVID A (President, CEO) — $35,381. Reynolds Mark (CFO) — $5,540. McKee Kelly T. Jr. (Chief Medical Officer) — $2,500.

The last purchase of 8,000 shares for transaction amount of $15,600 was made by DODD DAVID A (President, CEO) on 2024‑08‑09.

List of Insider Buy and Sell Transactions, GeoVax Labs, Inc.

2024-08-09PurchasePresident, CEO
8,000
0.1589%
$1.95$15,600+44.12%
2024-02-22PurchasePresident, CEO
8,209
0.431%
$2.27$18,663-8.22%
2024-02-21PurchasePresident, CEO
520
0.0257%
$2.15$1,118-8.64%
2024-02-07PurchaseCFO
2,000
0.0718%
$2.77$5,540-21.32%
2023-12-22PurchaseChief Medical Officer
6,944
0.0257%
$0.36$2,500+452.47%
2023-09-25PurchaseChief Medical Officer
9,653
0.0371%
$0.52$5,020+218.67%
2023-08-25PurchasePresident, CEO
35,087
0.1351%
$0.57$20,000+161.61%
2023-08-18PurchaseCFO
10,000
0.038%
$0.52$5,179+171.84%
2023-04-24PurchasePresident, CEO
32,000
0.122%
$0.64$20,445-10.61%
2023-04-20PurchaseCFO
8,000
0.0297%
$0.63$5,040-11.90%
2022-09-21Purchasedirector
10,000
0.043%
$1.10$11,000-39.22%
2022-07-01PurchaseVP, Business Development
1,000
0.0043%
$0.82$820-6.48%
2022-06-27PurchaseChief Medical Officer
4,464
0.0367%
$1.12$5,000-28.60%
2022-06-21Purchase
10,000
0.0761%
$1.21$12,100-38.32%
2022-05-05PurchaseChief Medical Officer
9,722
0.0758%
$0.72$7,000+11.57%
2022-05-04PurchaseChief Medical Officer
4,999
0.0362%
$0.71$3,549+5.19%
2011-12-30PurchaseCSO Emeritus
149,254
<0.0001%
$0.67$100,000
2011-12-30PurchasePresident, CEO
112,000
<0.0001%
$0.67$75,040
2011-12-30PurchaseCFO
15,000
<0.0001%
$0.67$10,050
2010-07-02PurchaseCFO
1,000
<0.0001%
$2.50$2,500

Insider Historical Profitability

<0.0001%
McKee Kelly T. Jr.Chief Medical Officer
35782
0.3792%
$2.3450<0.0001%
DODD DAVID APresident, CEO
26661
0.2825%
$2.3490<0.0001%
Reynolds MarkCFO
7213
0.0764%
$2.3490<0.0001%
EMORY UNIVERSITY10 percent owner
231070253
2448.7975%
$2.34024
ROBINSON HARRIET LCSO Emeritus
1201226
12.7302%
$2.3458
Tsolinas Peter Mdirector
431734
4.5754%
$2.3410
CHASE RANDAL Ddirector
36613
0.388%
$2.3420<0.0001%
HILDEBRAND DONALD Gdirector
19000
0.2014%
$2.3410
SPENCER JOHN N JRdirector
13700
0.1452%
$2.3440
MCNALLY ROBERT Tdirector
8300
0.088%
$2.3470
NEWMAN MARK JChief Scientific Officer
3000
0.0318%
$2.3410
Sharkey John W.VP, Business Development
2860
0.0303%
$2.3410<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.